Preclinical Testing of Combination Therapy for Malignant Tumors Arising from Neurofibromas
Abstract
About one half of Malignant Peripheral Nerve Sheath Tumors (MPNSTs) arise in Neurofibromatosis Type 1 patients (NF1). Currently, these tumors present very poor clinical prognosis, and despite efforts to find better chemotherapy, there has been little impact on overall patient survival. The extent of surgical resection is the best prognostic factor for these tumors. Our goal is to identify new combination of receptor tyrosine kinase inhibitors that are effective in cell culture and animal models of MPNSTs. We expect finding effective drug combinations that can be used to treat MPNST patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2011
- Accession Number
- ADA548839
Entities
People
- Gregory Riggins
Organizations
- Johns Hopkins University